Search research articles
Contact Us
Filters
Showing results (91-100 of 151) with videos related to
Page
of 16
Sort By:
Prostate Cancer and Prostatic Diseases
|
February 10, 2024
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis
Osama Mosalem, Winston Tan, Alan H Bryce, et al.
JAMA Oncology
|
November 3, 2022
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial
Mary L Nora Disis, Katherine A Guthrie, Ying Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 24, 2023
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer
Mary L Disis, Yushe Dang, Andrew L Coveler, et al.
Haematologica
|
April 3, 2025
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy
Yael Kusne, Osama M Mosalem, Jaxon Quillen, et al.
Breast Cancer Research and Treatment
|
February 1, 2008
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
Andrew L Coveler, Vivian Goodell, Devon J Webster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses
Denise L Cecil, John B Liao, Yushe Dang, et al.
Cell Death & Disease
|
November 23, 2013
Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1
C Rutherford, S Childs, J Ohotski, et al.
EJNMMI Research
|
March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting
Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 8, 2026
Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial
Michael Berger, Maryam Lustberg, Paul J Novotny, et al.
JAMA Oncology
|
January 24, 2017
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial
Lupe G Salazar, Hailing Lu, Jessica L Reichow, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 151) with videos related to
Sort By:
Page
of 16
Prostate Cancer and Prostatic Diseases
|
February 10, 2024
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis
Osama Mosalem, Winston Tan, Alan H Bryce, et al.
JAMA Oncology
|
November 3, 2022
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial
Mary L Nora Disis, Katherine A Guthrie, Ying Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 24, 2023
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer
Mary L Disis, Yushe Dang, Andrew L Coveler, et al.
Haematologica
|
April 3, 2025
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy
Yael Kusne, Osama M Mosalem, Jaxon Quillen, et al.
Breast Cancer Research and Treatment
|
February 1, 2008
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
Andrew L Coveler, Vivian Goodell, Devon J Webster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses
Denise L Cecil, John B Liao, Yushe Dang, et al.
Cell Death & Disease
|
November 23, 2013
Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1
C Rutherford, S Childs, J Ohotski, et al.
EJNMMI Research
|
March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting
Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 8, 2026
Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial
Michael Berger, Maryam Lustberg, Paul J Novotny, et al.
JAMA Oncology
|
January 24, 2017
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial
Lupe G Salazar, Hailing Lu, Jessica L Reichow, et al.
Page
of 16